Alpha IVF Group (0303) Fair Value & Analysis
Healthcare · MY · Market cap 1.2B MYR
Fair value as of: Jun 24, 2026
Analysis
Alpha IVF Group (0303) currently trades at 0.2450 MYR, while our model-based Fair Value estimate is 0.2100 MYR — implying the stock looks roughly 14.3% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Alpha IVF Group Berhad, together with its subsidiaries, operates as a fertility care specialist that focuses on the provision of assisted reproductive services in Malaysia, Singapore, Indonesia, China, Middle East, the Philippines, and internationally. The company offers assisted reproductive treatment services comprising ovulation induction, intra-uterine insemination, in-vitro fertilization treatment, intra-cytoplasmic sperm injection, gamete intrafallopian transfer, and savior sibling program; preimplantation genetic testing; implantation optimisation; sperm sorting; and egg freezing, embryo freezing and cryo-storage, laparoscopic surgery, hysteroscopic surgery, 4D ultrasound scanning, and artificial intelligence-enhanced embryo selection services. It also provides various diagnostics, testing and screening procedures; cryopreservation of eggs and sperms; medical consultants; fertility, gynecological, and obstetric treatment; and other women-related healthcare and medical service…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Alpha IVF Group (0303) undervalued?
What is the fair value of 0303?
What is the quality score of 0303?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.